Cargando…

A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro

Vascular calcification (VC) and osteoporosis are age-related diseases and significant risk factors for the mortality of elderly. VC and osteoporosis may share common risk factors such as renin-angiotensin system (RAS)-related hypertension. In fact, inhibitors of RAS pathway, such as angiotensin type...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Seongtae, Lee, Bok-Sim, Jung, Seung Eun, Yoon, Yoojin, Song, Byeong-Wook, Kim, Il-Kwon, Choi, Jung-Won, Kim, Sang Woo, Lee, Seahyoung, Lim, Soyeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967071/
https://www.ncbi.nlm.nih.gov/pubmed/36838684
http://dx.doi.org/10.3390/molecules28041693
_version_ 1784897173907832832
author Jeong, Seongtae
Lee, Bok-Sim
Jung, Seung Eun
Yoon, Yoojin
Song, Byeong-Wook
Kim, Il-Kwon
Choi, Jung-Won
Kim, Sang Woo
Lee, Seahyoung
Lim, Soyeon
author_facet Jeong, Seongtae
Lee, Bok-Sim
Jung, Seung Eun
Yoon, Yoojin
Song, Byeong-Wook
Kim, Il-Kwon
Choi, Jung-Won
Kim, Sang Woo
Lee, Seahyoung
Lim, Soyeon
author_sort Jeong, Seongtae
collection PubMed
description Vascular calcification (VC) and osteoporosis are age-related diseases and significant risk factors for the mortality of elderly. VC and osteoporosis may share common risk factors such as renin-angiotensin system (RAS)-related hypertension. In fact, inhibitors of RAS pathway, such as angiotensin type 1 receptor blockers (ARBs), improved both vascular calcification and hip fracture in elderly. However, a sex-dependent discrepancy in the responsiveness to ARB treatment in hip fracture was observed, possibly due to the estrogen deficiency in older women, suggesting that blocking the angiotensin signaling pathway may not be effective to suppress bone resorption, especially if an individual has underlying osteoclast activating conditions such as estrogen deficiency. Therefore, it has its own significance to find alternative modality for inhibiting both vascular calcification and osteoporosis by directly targeting osteoclast activation to circumvent the shortcoming of ARBs in preventing bone resorption in estrogen deficient individuals. In the present study, a natural compound library was screened to find chemical agents that are effective in preventing both calcium deposition in vascular smooth muscle cells (vSMCs) and activation of osteoclast using experimental methods such as Alizarin red staining and Tartrate-resistant acid phosphatase staining. According to our data, citreoviridin (CIT) has both an anti-VC effect and anti-osteoclastic effect in vSMCs and in Raw 264.7 cells, respectively, suggesting its potential as an effective therapeutic agent for both VC and osteoporosis.
format Online
Article
Text
id pubmed-9967071
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99670712023-02-26 A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro Jeong, Seongtae Lee, Bok-Sim Jung, Seung Eun Yoon, Yoojin Song, Byeong-Wook Kim, Il-Kwon Choi, Jung-Won Kim, Sang Woo Lee, Seahyoung Lim, Soyeon Molecules Article Vascular calcification (VC) and osteoporosis are age-related diseases and significant risk factors for the mortality of elderly. VC and osteoporosis may share common risk factors such as renin-angiotensin system (RAS)-related hypertension. In fact, inhibitors of RAS pathway, such as angiotensin type 1 receptor blockers (ARBs), improved both vascular calcification and hip fracture in elderly. However, a sex-dependent discrepancy in the responsiveness to ARB treatment in hip fracture was observed, possibly due to the estrogen deficiency in older women, suggesting that blocking the angiotensin signaling pathway may not be effective to suppress bone resorption, especially if an individual has underlying osteoclast activating conditions such as estrogen deficiency. Therefore, it has its own significance to find alternative modality for inhibiting both vascular calcification and osteoporosis by directly targeting osteoclast activation to circumvent the shortcoming of ARBs in preventing bone resorption in estrogen deficient individuals. In the present study, a natural compound library was screened to find chemical agents that are effective in preventing both calcium deposition in vascular smooth muscle cells (vSMCs) and activation of osteoclast using experimental methods such as Alizarin red staining and Tartrate-resistant acid phosphatase staining. According to our data, citreoviridin (CIT) has both an anti-VC effect and anti-osteoclastic effect in vSMCs and in Raw 264.7 cells, respectively, suggesting its potential as an effective therapeutic agent for both VC and osteoporosis. MDPI 2023-02-10 /pmc/articles/PMC9967071/ /pubmed/36838684 http://dx.doi.org/10.3390/molecules28041693 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jeong, Seongtae
Lee, Bok-Sim
Jung, Seung Eun
Yoon, Yoojin
Song, Byeong-Wook
Kim, Il-Kwon
Choi, Jung-Won
Kim, Sang Woo
Lee, Seahyoung
Lim, Soyeon
A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro
title A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro
title_full A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro
title_fullStr A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro
title_full_unstemmed A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro
title_short A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro
title_sort low concentration of citreoviridin prevents both intracellular calcium deposition in vascular smooth muscle cell and osteoclast activation in vitro
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967071/
https://www.ncbi.nlm.nih.gov/pubmed/36838684
http://dx.doi.org/10.3390/molecules28041693
work_keys_str_mv AT jeongseongtae alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro
AT leeboksim alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro
AT jungseungeun alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro
AT yoonyoojin alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro
AT songbyeongwook alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro
AT kimilkwon alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro
AT choijungwon alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro
AT kimsangwoo alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro
AT leeseahyoung alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro
AT limsoyeon alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro
AT jeongseongtae lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro
AT leeboksim lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro
AT jungseungeun lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro
AT yoonyoojin lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro
AT songbyeongwook lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro
AT kimilkwon lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro
AT choijungwon lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro
AT kimsangwoo lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro
AT leeseahyoung lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro
AT limsoyeon lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro